IDiyas

For the Inventor, By the Inventor

Newtown, PA, United States of America

Stephen P O'Connor

USPTO Granted Patents = 10 

Average Co-Inventor Count = 3.8

ph-index = 5

Forward Citations = 108(Granted Patents)


Location History:

  • Newtown, PA (US) (2003 - 2007)
  • Lambertville, NJ (US) (2001 - 2008)
  • Stockton, NJ (US) (2009)
  • Princeton, NJ (US) (2013)
  • Hopewell, NJ (US) (2013)
  • Asbury Park, NJ (US) (2017)

Company Filing History:

goldMedal10 out of 3,681 
 
Bristol-myers Squibb Compnay
 patents

Years Active: 2001-2017

Loading Chart...
10 patents (USPTO):Explore Patents
1. 9604964 - Dihydropyrazole GPR40 modulators (2017-03-28),
2. 8546394 - Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors (2013-10-01),
3. 8415367 - Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators (2013-04-09),
4. 7488725 - Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods (2009-02-10),
5. 7420059 - HMG-CoA reductase inhibitors and method (2008-09-02),
6. 7166586 - Sulfonamide lactam inhibitors of FXa and method (2007-01-23),
7. 6555542 - Sulfonamide lactam inhibitors of FXa and method (2003-04-29),
8. 6544981 - Lactam inhibitors of factor Xa and method (2003-04-08),
9. 6511973 - Lactam inhibitors of FXa and method (2003-01-28),
10. 6297233 - Lactam inhibitors of FXa and method (2001-10-02),

Title: Innovator Profile: Stephen P. O'Connor from Newtown, PA

Introduction

Stephen P. O'Connor is a distinguished inventor based in Newtown, Pennsylvania. With an impressive portfolio of ten patents, he has made significant contributions to the field of medicinal chemistry. His work primarily focuses on innovative compounds that target specific biological pathways.

Latest Patents

O'Connor's latest patents include groundbreaking compounds such as Dihydropyrazole GPR40 modulators. The invention encompasses compounds of Formula (I), which are aimed at modulating the G protein-coupled receptor GPR40. These compounds present potential therapeutic applications as medicaments. Additionally, his patent of Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors introduces innovative inhibitors that could be instrumental in treating diseases requiring such therapies. The structure of these compounds serves to provide novel therapeutic options for patients.

Career Highlights

O'Connor is currently employed at Bristol-Myers Squibb Company, a prominent leader in the pharmaceutical industry. His tenure there has provided him with a platform to develop and patent his innovative ideas, contributing to the advancement of medical science. His inventiveness is marked by a robust focus on creating solutions that could improve patient outcomes.

Collaborations

Throughout his career, Stephen P. O'Connor has collaborated with notable colleagues such as Yan Shi and Philip D. Stein. These collaborations have fostered a creative environment that promotes the exchange of ideas and the development of new therapeutic approaches.

Conclusion

In conclusion, Stephen P. O'Connor is a notable inventor whose work has the potential to impact the pharmaceutical landscape significantly. With a strong patent portfolio and valuable collaborations, he continues to push the boundaries of innovation in the field of medicine. His focus on developing novel compounds showcases his commitment to improving health outcomes through scientific advancement.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…